Bridges Investment Counsel Inc. Has $3.86 Million Holdings in Johnson & Johnson (JNJ)
Bridges Investment Counsel Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 58.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,657 shares of the company’s stock after selling 41,987 shares during the quarter. Johnson & Johnson accounts for 2.1% of Bridges Investment Counsel Inc.’s investment portfolio, making the stock its 12th largest position. Bridges Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $3,856,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of JNJ. Curbstone Financial Management Corp increased its position in shares of Johnson & Johnson by 99.1% during the third quarter. Curbstone Financial Management Corp now owns 30,400 shares of the company’s stock worth $3,952,000 after purchasing an additional 15,134 shares in the last quarter. Bogart Wealth LLC increased its position in shares of Johnson & Johnson by 6.7% during the second quarter. Bogart Wealth LLC now owns 6,006 shares of the company’s stock worth $795,000 after purchasing an additional 378 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $1,415,000. W. E. Donoghue & Co. LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $16,120,000. Finally, Pinnacle Family Advisors LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $209,000. Institutional investors and hedge funds own 65.70% of the company’s stock.
Several analysts recently commented on JNJ shares. Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, August 24th. UBS reiterated an “underweight” rating on shares of Johnson & Johnson in a research report on Thursday, August 24th. BMO Capital Markets reiterated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research report on Monday, September 18th. Finally, Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $145.04.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.68 EPS. equities research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.37%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/bridges-investment-counsel-inc-has-3-86-million-holdings-in-johnson-johnson-jnj/1773991.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.